ONCONETIX INC (ONCO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.02+38.02%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ONCO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -80.4% |
| Our one-year growth estimate | diamond | 34.1% |
Growth built into the price is above our model estimate.
The price assumes 114.6 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
ONCO — dividend update
Dated 2026-07-29
Entry into a Material Definitive Agreement PIPE Financing On July 28, 2026, Onconetix, Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with an accredited investor (the “ PIPE Investor ”), pursuant to which the Company agreed to issue and sell to the PIPE Investor an aggregate of 37,812 shares of Series F convertible preferred stock, par value $0.00001 per share (“ Series F Preferred Stock ”), for an aggregate…
Why it matters: The PRIME study is crucial for validating Proclarix in the U.S. market. Positive results could boost market acceptance.
Supportive ifThe PRIME study shows Proclarix helps cut down on unnecessary biopsies.
Worry ifThe PRIME study shows no big improvements over current methods.
Why it matters: New partnerships could expand Proclarix's market reach. This would support growth in revenue and market presence.
Supportive ifAnnouncement of at least one new partnership in Europe for Proclarix within the next quarter.
Worry ifNo new partnerships announced in Europe within the next quarter.
Why it matters: Progress on this partnership could drive future growth for ONCONETIX. Investors will look for signs of success.
Supportive ifA press release will announce a big milestone or agreement with Realbotix.
Worry ifNo updates or setbacks in the partnership discussions for over six months.
Why it matters: The acquisition is a growth priority. Progress could signal future revenue potential.
Supportive ifOnconetix says it has made more money from Realbotix.
Worry ifThere are no updates or bad news about the acquisition.
Why it matters: This split aims to maintain compliance with Nasdaq's listing requirements. It could affect investor perception and stock liquidity.
Watch forThe stock maintains a bid price above $1.00 per share for at least 30 days post-split.
Also watch forThe stock price falls below $1.00 per share within 30 days post-split.
Why it matters: Earnings results will provide insight into financial health and operational progress. Low revenue may raise concerns.
Worry ifQ2 revenue exceeds $50,000, indicating growth.
Less concerning ifQ2 revenue is still under $21,457, showing ongoing money issues.
Why it matters: Expanding Proclarix's presence in Europe is key for revenue growth. Progress here could signal broader market acceptance.
Supportive ifNew deals or sales in Europe show strong growth for Proclarix.
Worry ifNo new deals or slow sales in Europe.
Why it matters: The PRIME study is crucial for validating Proclarix in the U.S. market. Positive updates could enhance market confidence.
Supportive ifLook for news about big enrollment milestones or good results from the PRIME study.
Worry ifNo updates or negative results from the PRIME study within the next quarter.
Why it matters: The PIPE financing helps support operations. Better financial numbers may show good capital use.
Watch forQuarterly reports show better cash flow or smaller losses after PIPE financing.
Also watch forQuarterly reports show ongoing losses or worse cash flow even after PIPE financing.
Why it matters: The capital raise is crucial for sustaining operations amid losses. It may signal financial health moving forward.
Watch forThe company reports improved cash flow or reduced losses in the next quarter.
Also watch forWatch for ongoing cash flow problems or bigger losses even after the capital raise.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$471 on $10,000 · ±4.7% | How much price usually moves either way. |
| Bad day | $1,620 loss on $10,000 · 16.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,970 loss on $10,000 · 99.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.